Drug intelligence / Profile preview

AXP1020

Development stage: Unknown
Lead developer: Xiamen Innovax Biotech
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

AXP1020 is a recombinant trivalent rotavirus subunit vaccine developed by Sino-Innovax Biotech (Xiamen Innovax Biotech) in collaboration with Xiamen University and Wantai BioPharm. Expressed using an *Escherichia coli* expression system, the vaccine contains a truncated version of the rotavirus spike protein VP4 (specifically targeting the P[4], P[6], and P[8] genotypes). It is designed to prevent rotavirus gastroenteritis in infants and young children by inducing neutralizing antibodies against rotavirus. AXP1020 is currently in Phase I clinical development following CTA approval in China.

Other names: recombinant trivalent rotavirus subunit vaccinerecombinant trivalent rotavirus subunit vaccine (E. coli)重组三价轮状病毒亚单位疫苗(大肠埃希菌)

Targets

VP4 (Rotavirus VP4)

Beyond the preview

Go deeper on AXP1020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AXP1020.

Explore the full profile